

Characteristics	Low expression of GSDMA	High expression of GSDMA	P value
n	250	251	
PSA(ng/ml), n (%)			0.535
< 4	211 (47.5%)	206 (46.4%)	
>= 4	12 (2.7%)	15 (3.4%)	
Gleason score, n (%)			< 0.001
6	34 (6.8%)	12 (2.4%)	
7	129 (25.7%)	119 (23.8%)	
8&9&10	87 (17.4%)	120 (24%)	
Clinical T stage, n (%)			0.318
T1	100 (24.6%)	77 (18.9%)	
T2	90 (22.1%)	85 (20.9%)	
T3&T4	25 (6.1%)	30 (7.4%)	

Characteristics	Low expression of GSDMB	High expression of GSDMB	P value
n	250	251	
PSA(ng/ml), n (%)			0.551
< 4	210 (47.3%)	207 (46.6%)	
>= 4	12 (2.7%)	15 (3.4%)	
Gleason score, n (%)			< 0.001
6	25 (5%)	21 (4.2%)	
7	151 (30.1%)	97 (19.4%)	
8&9&10	74 (14.8%)	133 (26.5%)	
Clinical T stage, n (%)			0.260
T1	95 (23.3%)	82 (20.1%)	
T2	81 (19.9%)	94 (23.1%)	
T3&T4	24 (5.9%)	31 (7.6%)	

Characteristics	Low expression of GSDMC	High expression of GSDMC	P value
n	250	251	
PSA(ng/ml), n (%)			0.188
< 4	209 (47.1%)	208 (46.8%)	
>= 4	10 (2.3%)	17 (3.8%)	
Gleason score, n (%)			0.644
6	22 (4.4%)	24 (4.8%)	
7	129 (25.7%)	119 (23.8%)	
8&9&10	99 (19.8%)	108 (21.6%)	
Clinical T stage, n (%)			0.033
T1	101 (24.8%)	76 (18.7%)	
T2	84 (20.6%)	91 (22.4%)	
T3&T4	21 (5.2%)	34 (8.4%)	

Characteristics	Low expression of GSDMD	High expression of GSDMD	P value
n	250	251	
PSA(ng/ml), n (%)			0.070
< 4	214 (48.2%)	203 (45.7%)	
>= 4	9 (2%)	18 (4.1%)	
Gleason score, n (%)			0.644
6	22 (4.4%)	24 (4.8%)	
7	129 (25.7%)	119 (23.8%)	
8&9&10	99 (19.8%)	108 (21.6%)	
Clinical T stage, n (%)			0.721
T1	90 (22.1%)	87 (21.4%)	
T2	83 (20.4%)	92 (22.6%)	
T3&T4	29 (7.1%)	26 (6.4%)	

Characteristics	Low expression of GSDMD	High expression of GSDMD	P value
n	250	251	
PSA(ng/ml), n (%)			0.165
< 4	205 (46.2%)	212 (47.7%)	
>= 4	17 (3.8%)	10 (2.3%)	
Gleason score, n (%)			0.129
6	27 (5.4%)	19 (3.8%)	
7	130 (25.9%)	118 (23.6%)	
8&9&10	93 (18.6%)	114 (22.8%)	
Clinical T stage, n (%)			0.816
T1	93 (22.9%)	84 (20.6%)	
T2	86 (21.1%)	89 (21.9%)	
T3&T4	28 (6.9%)	27 (6.6%)	

Characteristics	Low expression of PJVK	High expression of PJVK	P value
n	250	251	
PSA(ng/ml), n (%)			0.309
< 4	205 (46.2%)	212 (47.7%)	
>= 4	16 (3.6%)	11 (2.5%)	
Gleason score, n (%)			0.008
6	21 (4.2%)	25 (5%)	
7	141 (28.1%)	107 (21.4%)	
8&9&10	88 (17.6%)	119 (23.8%)	
Clinical T stage, n (%)			0.812
T1	86 (21.1%)	91 (22.4%)	
T2	91 (22.4%)	84 (20.6%)	
T3&T4	28 (6.9%)	27 (6.6%)	

